All In Biotech

Drug Trial Radar · NCT01208766

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,503 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,503

Actual

Start

Jan 2011

Primary completion

Dec 2020

Study completion Jan 2025

Sponsor

Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Myeloma Network B.V.; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM (Deutsche Studiengruppe Multiples Myelom); NMSG (Nordic Myeloma Study Group); Central European Myeloma Study Group
First posted
Sep 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study phase: phase III Study objective: * Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT) * Comparison of Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no consolidation * Comparison of single versus tandem high dose Melphalan with ASCT Patient population: Patients with symptomatic multiple myeloma,previously untreated, ISS stages 1-3, age 18-65 years inclusive Study design: Prospective, multicenter, intergroup, randomized Duration of treatment: Expected duration of induction, stem cell collection and intensification is 6 - 9 months. Consolidation with VRD will last 2 months Maintenance therapy with Lenalidomide will be given until relapse. All patients will be followed until 10 years after registration.

Conditions

  • Multiple Myeloma

Interventions

  • Bortezomib, Melphalan, Prednisone (VMP)Drug

    * Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11,22,25,29,32 * Melphalan \_ 9 mg/m² \_ p.o. \_ days 1-4 * Prednisone \_ 60 mg/m² \_ p.o. \_ days 1-4

  • 1 or 2 cycle(s) HDM (High Dose Melphalan)Drug

    \- Melphalan \_ 100 mg/m² \_ i.v. rapid infusion \_ -3, -2\* \*Patients with renal insufficiency 100 mg/m2 only at day -3 If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.

  • 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)Drug

    * Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11 * Lenalidomide \_ 25 mg \_ p.o. \_ days 1-21 * Dexamethasone \_ 20 mg \_ p.o. \_ days 1,2,4,5,8,9,11,12

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).Time frame: end of trial (last patient last visit)
  2. For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes firstTime frame: end of trial (last patient last visit)
  3. For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes firstTime frame: end of trial (last patient last visit)

Locations

208 sites in 16 countries. Site status is shown where the registry gives one.

  • AU-Brisbane-PAH

    Brisbane, Australia

  • AU-Canberra-CANBERRAHOSPITAL

    Canberra, Australia

  • AU-Melbourne-ALFRED

    Melbourne, Australia

  • AU-Sydney-CONCORD

    Sydney, Australia

  • AU-Sydney-NEPEAN

    Sydney, Australia

  • Prince of Wales Hospital

    Sydney, Australia

  • St George Hospital

    Sydney, Australia

  • Krankenhaus d.Elisabethinen

    Linz, Austria

  • Landeskrankenhaus Salzburg

    Salzburg, Austria

  • AT-Vienna-HANUSCH

    Vienna, Austria

  • BE-Antwerpen Edegem-UZA

    Antwerp, Belgium

  • BE-Antwerpen-ZNASTUIVENBERG

    Antwerp, Belgium

  • BE-Haine-Saint-Paul-JOLIMONT

    Haine-Saint-Paul, Belgium

  • CHU Tivoli

    La Louvière, Belgium

  • BE-Liege-CHRCITADELLE

    Liège, Belgium

  • BE-Mons-AMBROISE

    Mons, Belgium

  • CHR Saint Joseph

    Mons, Belgium

  • BE-Roeselare-AZDELTA

    Roeselare, Belgium

  • RHMS

    Saint-Ghislain, Belgium

  • CH Wapi

    Tournai, Belgium

  • AZ Turnhout

    Turnhout, Belgium

  • CZ-Brno-UHBRNO

    Brno, Czechia

  • Kralove-University Hospital Hradec Kralove

    Hradec, Czechia

  • CZ-Olomouc-FNOL

    Olomouc, Czechia

  • CZ-Ostrava-Poruba-FNO

    Ostrava, Czechia

  • University Hospital Plzen

    Pilsen, Czechia

  • University Hospital Kralovske Vinohrady

    Prague, Czechia

  • DK-Aalborg-AALBORGUH

    Aalborg, Denmark

  • DK-Aarhus N-AUH

    Aarhus, Denmark

  • DK-Copenhagen-RIGSHOSPITALET

    Copenhagen, Denmark

  • DK-Herlev-HERLEV

    Herlev, Denmark

  • DK-Odense-OUH

    Odense, Denmark

  • DK-Roskilde-ROSKILDE

    Roskilde, Denmark

  • FI-Turku-TYKS

    Turku, Finland

  • GR-Athens-ALEXANDRA

    Athens, Greece

  • St. Istvan and St. Laszlo Korhaz Hospital

    Budapest, Hungary

  • Szeged University Hospital

    Szeged, Hungary

  • SS Antonio e Biogio

    Alessandria, Italy

  • AOU Umberto I-Clinica di Ematologica

    Ancona, Italy

  • Ospedale C. e G. Mazzoni-Ematologia

    Ascoli Piceno, Italy

Showing 40 of 208 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.